MMWR Morb Mortal Wkly Rep. 2023 Jan 20;72(3):73-75. doi: 10.15585/mmwr.mm7203a5.
Bivalent COVID-19 booster vaccines, developed to protect against both ancestral and Omicron BA.4/BA.5 variants, are recommended to increase protection against SARS-CoV-2 infection and severe disease* (1,2). However, relatively few eligible U.S. adults have received a bivalent booster dose (3), and reasons for low coverage are unclear. An opt-in Internet survey of 1,200 COVID-19-vaccinated U.S. adults was conducted to assess reasons for receiving or not receiving a bivalent booster dose. Participants could select multiple reasons from a list of suggested reasons to report why they had or had not received a bivalent booster dose. The most common reasons cited for not receiving the bivalent booster dose were lack of awareness of eligibility for vaccination (23.2%) or of vaccine availability (19.3%), and perceived immunity against infection (18.9%). After viewing information about eligibility and availability, 67.8% of participants who had not received the bivalent booster dose indicated that they planned to do so; in a follow-up survey 1 month later, 28.6% of these participants reported having received the dose. Among those who had planned to receive the booster dose but had not yet done so, 82.6% still intended to do so. Participants who had still not received the booster dose most commonly reported being too busy to get vaccinated (35.6%). To help increase bivalent booster dose coverage, health care and public health professionals should use evidence-based strategies to convey information about booster vaccination recommendations and waning immunity (4), while also working to increase convenient access.
二价 COVID-19 加强疫苗旨在预防原始株和奥密克戎 BA.4/BA.5 变异株,建议接种以提高对 SARS-CoV-2 感染和重症的保护*(1,2)。然而,相对较少的符合条件的美国成年人接种了二价加强针(3),且覆盖率低的原因尚不清楚。一项针对 1200 名接种过 COVID-19 疫苗的美国成年人的选择加入式互联网调查,旨在评估接种或未接种二价加强针的原因。参与者可以从列出的建议原因中选择多个原因,报告他们接种或未接种二价加强针的原因。未接种二价加强针的最常见原因是缺乏对疫苗接种资格(23.2%)或疫苗供应(19.3%)的认识,以及对感染免疫力的认知(18.9%)。在查看有关资格和供应的信息后,67.8%未接种二价加强针的参与者表示他们计划接种;在一个月后的后续调查中,其中 28.6%的参与者报告已接种该剂量。在那些计划接种加强针但尚未接种的人中,82.6%的人仍打算接种。那些仍未接种加强针的人最常报告因太忙而无法接种疫苗(35.6%)。为了提高二价加强针的覆盖率,医疗保健和公共卫生专业人员应使用循证策略来传达关于加强针接种建议和免疫力下降的信息(4),同时努力增加便利的接种途径。